SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


       Date of Report (date of earliest event reported): December 14, 2007

                        TIAN'AN PHARMACEUTICAL CO., LTD.
                        --------------------------------
             (Exact name of Registrant as specified in its charter)


       Nevada                          None                  None
---------------------------------------------------------------------------
(State or other jurisdiction   (Commission File No.)    (IRS Employer
of incorporation)                                     Identification No.)


                      Level 11, International Trade Centre,
                           No. 196 Xiaozhai East Road
                                  Xi'an, China
                  -------------------------------------------
          (Address of principal executive offices, including Zip Code)


      Registrant's telephone number, including area code: 0086-29-85381586


                                       N/A
                   ------------------------------------------
          (Former name or former address if changed since last report)



<PAGE>


Item 4.01   Change in Registrant's Certifying Accountant

     Effective  December 14, 2007 Michael  Pollack CPA resigned as the Company's
independent  certified  public  accountant.  Mr.  Pollack  audited the Company's
financial  statements for the fiscal years ended December 31, 2006 and 2005. The
reports  of Mr.  Pollack  for these  fiscal  years did not  contain  an  adverse
opinion, or disclaimer of opinion and were not qualified or modified as to audit
scope or  accounting  principles.  During the  Company's  two most recent fiscal
years and  subsequent  interim  period  ended  December  14,  2007 there were no
disagreements  with Mr.  Pollack  on any  matter  of  accounting  principles  or
practices, financial statement disclosure or auditing scope or procedures, which
disagreements,  if not resolved to the  satisfaction of Mr. Pollack,  would have
caused him to make reference to such disagreements in his report.

     Effective February 14, 2008 the Company hired Wen Jiang & Company PC as the
Company's independent registered public accounting firm.

     Wen Jiang & Company did not provide the Company with advice  regarding  the
application  of  accounting  principles  to  a  specified  transaction,   either
completed  or proposed,  or the type of audit  opinion that might be rendered on
the Company's financial  statements,  that was an important factor considered by
the Company in reaching a decision as to an  accounting,  auditing or  financial
reporting issue.  During the two most recent fiscal years and subsequent interim
period  ended  February 4, 2008,  the  Company did not consult  with Wen Jiang &
Company  regarding  any  matter  that was the  subject  of a  disagreement  or a
reportable  event as defined in the  regulations  of the Securities and Exchange
Commission.

     The Company has authorized  Mr.  Pollack to discuss any matter  relating to
the Company and its operations with Wen Jiang & Company.

     The  decision  to hire Wen Jiang &  Company  as the  Company's  independent
registered  public  accountants was recommended and approved by the directors of
the Company. The Company does not have an audit committee.

     Wen Jiang & Company has  reviewed  the  disclosures  contained  in this 8-K
report.  The Company has advised Wen Jiang & Company that it has the opportunity
to furnish the Company with a letter  addressed to the  Securities  and Exchange
Commission concerning any new information,  clarifying the Company's disclosures
herein,  or stating  any reason why Wen Jiang & Company  does not agree with any
statements  made by the Company in this report.  Wen Jiang & Company has advised
the  Company  that  nothing  has come to its  attention  which would cause it to
believe that any such letter was necessary.


                                       2

<PAGE>


Item 9.01         Financial Statements and Exhibits

   (d)  Exhibits

      16. Letter from the Company's former independent registered public
accountant will be filed by amendment.






                                       3

<PAGE>


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:    February 14, 2008
                                 TIAN'AN PHARMACEUTICAL CO., LTD.


                                 By: /s/ Weng Jianjun
                                    ---------------------------------------
                                    Weng Jianjun, Principal Executive Officer
[{"type": "8-K", "sequence": "1", "filename": "form8kchgauditor2-08.txt", "secsgml_size_bytes": 5043}]
{"company-data": {"conformed-name": "Tian'an Pharmaceutical Co., Ltd.", "cik": "0001366581", "assigned-sic": "2834", "irs-number": "000000000"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-135434", "film-number": "08612436"}, "business-address": {"street1": "2/F NO. 18 BUILDING, HUOJU ROAD, EAST", "street2": "DEVELOPMENT ZONE", "city": "XI'AN", "state": "F4", "zip": "00000", "phone": "0086-29-85381586"}, "mail-address": {"street1": "2/F NO. 18 BUILDING, HUOJU ROAD, EAST", "street2": "DEVELOPMENT ZONE", "city": "XI'AN", "state": "F4", "zip": "00000"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): December 14, 2007

                        TIAN'AN PHARMACEUTICAL CO., LTD.
                        --------------------------------
             (Exact name of Registrant as specified in its charter)

       Nevada                          None                  None
---------------------------------------------------------------------------
(State or other jurisdiction   (Commission File No.)    (IRS Employer
of incorporation)                                     Identification No.)

                      Level 11, International Trade Centre,
                           No. 196 Xiaozhai East Road
                                  Xi'an, China
                  -------------------------------------------
          (Address of principal executive offices, including Zip Code)

      Registrant's telephone number, including area code: 0086-29-85381586

                                       N/A
                   ------------------------------------------
          (Former name or former address if changed since last report)
Item 4.01   Change in Registrant's Certifying Accountant

     Effective  December 14, 2007 Michael  Pollack CPA resigned as the Company's
independent  certified  public  accountant.  Mr.  Pollack  audited the Company's
financial  statements for the fiscal years ended December 31, 2006 and 2005. The
reports  of Mr.  Pollack  for these  fiscal  years did not  contain  an  adverse
opinion, or disclaimer of opinion and were not qualified or modified as to audit
scope or  accounting  principles.  During the  Company's  two most recent fiscal
years and  subsequent  interim  period  ended  December  14,  2007 there were no
disagreements  with Mr.  Pollack  on any  matter  of  accounting  principles  or
practices, financial statement disclosure or auditing scope or procedures, which
disagreements,  if not resolved to the  satisfaction of Mr. Pollack,  would have
caused him to make reference to such disagreements in his report.

     Effective February 14, 2008 the Company hired Wen Jiang & Company PC as the
Company's independent registered public accounting firm.

     Wen Jiang & Company did not provide the Company with advice  regarding  the
application  of  accounting  principles  to  a  specified  transaction,   either
completed  or proposed,  or the type of audit  opinion that might be rendered on
the Company's financial  statements,  that was an important factor considered by
the Company in reaching a decision as to an  accounting,  auditing or  financial
reporting issue.  During the two most recent fiscal years and subsequent interim
period  ended  February 4, 2008,  the  Company did not consult  with Wen Jiang &
Company  regarding  any  matter  that was the  subject  of a  disagreement  or a
reportable  event as defined in the  regulations  of the Securities and Exchange
Commission.

     The Company has authorized  Mr.  Pollack to discuss any matter  relating to
the Company and its operations with Wen Jiang & Company.

     The  decision  to hire Wen Jiang &  Company  as the  Company's  independent
registered  public  accountants was recommended and approved by the directors of
the Company. The Company does not have an audit committee.

     Wen Jiang & Company has  reviewed  the  disclosures  contained  in this 8-K
report.  The Company has advised Wen Jiang & Company that it has the opportunity
to furnish the Company with a letter  addressed to the  Securities  and Exchange
Commission concerning any new information,  clarifying the Company's disclosures
herein,  or stating  any reason why Wen Jiang & Company  does not agree with any
statements  made by the Company in this report.  Wen Jiang & Company has advised
the  Company  that  nothing  has come to its  attention  which would cause it to
believe that any such letter was necessary.

                                       2
Item 9.01         Financial Statements and Exhibits

   (d)  Exhibits

      16. Letter from the Company's former independent registered public
accountant will be filed by amendment.

                                       3
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:    February 14, 2008
                                 TIAN'AN PHARMACEUTICAL CO., LTD.

                                 By: /s/ Weng Jianjun
                                    ---------------------------------------
                                    Weng Jianjun, Principal Executive Officer